Slides
Page 1
November 5, 2025 Innovating to Transform the Lives of Patients and Their Families 2025 Third Quarter Financial Results November 5, 2025 Markella EPIDIOLEX ® patient diagnosed with Dravet syndrome
Page 2
November 5, 2025 Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements 2 This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, including the Company’s 2025 financial guidance and the Company’s expectations related thereto, including with respect to tariffs, and anticipated catalysts; the Company’s expectations for total revenue growth; expectations that Epidiolex will reach blockbuster status in 2025; the Company’s development, regulatory and commercialization strategy; the Company’s expectations with respect to potential corporate development; the advancement of pipeline programs and the timing of development activities, regulatory activities and submissions related thereto; the Company’s expectations with respect to its products and product candidates and the potential of the Company’s products and product candidates; the Company’s capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; growing and diversifying the Company’s revenue, investing in its pipeline of novel therapies, and delivering innovative therapies for patients and potential benefits of such therapies; the Company’s ability to realize the commercial potential of its products; the Company’s net product sales and goals for net product sales from new and acquired products; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof; the Company’s clinical trials confirming clinical benefit or enabling regulatory submissions; planned or anticipated regulatory submissions and filings, and the anticipated timing thereof; potential regulatory approvals; and other statements that are not historical facts. These forward-looking statements are based on the Company’s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from Xywav, Rylaze, Epidiolex/Epidyolex and other products; Epidiolex realizing its blockbuster potential; the introduction of new products into the U.S. market that compete with, or otherwise disrupt the market for, the Company’s oxybate products and other products and product candidates; effectively launching and commercializing the Company’s other products and product candidates; the successful completion of development and regulatory activities with respect to the Company’s product candidates; obtaining and maintaining adequate coverage and reimbursement for the Company’s products; the time-consuming and uncertain regulatory approval process, including the risk that the Company’s current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company’s business operations and financial results; geopolitical events, including the conflict between Russia and Ukraine and related sanctions; macroeconomic conditions, including global financial markets, rising interest rates and inflation, international tariffs and trade restrictions, and potential banking disruptions; regulatory initiatives and changes in tax laws; market volatility; protecting and enhancing the Company’s intellectual property rights and the Company’s commercial success being dependent upon the Company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; the ability of the parties to obtain court approval of certain Xyrem class action settlement agreements and the risk that the Company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including delays or problems in the supply or manufacture of the Company’s products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired product candidates, products and businesses, including Chimerix and the acquired product Modeyso; the Company’s ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the Company’s cash flows and capital resources; the Company’s ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company’s ability to meet its projected long-term goals and objectives, in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company’s long-term goals and objectives; fluctuations in the market price and trading volume of the Company’s ordinary shares; restrictions on repurchases of capital stock; the timing and availability of alternative investment opportunities; and other risks and uncertainties affecting the Company, including those described from time to time under the caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals’ Securities and Exchange Commission filings and reports, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 as supplemented by the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and future filings and reports by the Company. Other risks and uncertainties of which the Company is not currently aware may also affect the Company’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.
Page 3
November 5, 2025 Transforming Lives. Redefining Possibilities. 3 Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. GAAP the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation. The Company presents non-GAAP ANI (and the related per share measure) and certain line item components. Non-GAAP ANI (and the related per share measure) and its line item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow in the Appendix hereto, and in the case of non-GAAP ANI (and the related per share measure), adjust for the income tax effect of the non- GAAP adjustments. In this regard, the components of non-GAAP ANI, including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP ANI measure. The Company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the Company’s financial information prepared in accordance with GAAP , can enhance investors’ and analysts' ability to meaningfully compare the Company’s results from period to period and to its forward-looking guidance, and to identify operating trends in the Company’s business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the Company’s financial performance. The Company’s management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the Company’s business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for the Company’s management, the Company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the Company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. In this regard, commencing with the first quarter of 2025, the company is no longer including an adjustment for non-cash interest expense in the company's non-GAAP adjusted financial measures. For purposes of comparability, non-GAAP adjusted financial measures for 2024 have been updated to reflect this change. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the Company in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
Page 4
4 Introduction and Overview Renee Gala President and Chief Executive Officer November 5, 2025
Page 5
November 5, 2025 Strong 2025 Execution and Continued Focus on Growth 5 COMMERCIAL Highest ever quarterly revenue reflects continued execution PIPELINE Key opportunities across pipeline FINANCIAL Disciplined capital allocation enables investment in growth Sleep1: • Xywav® revenues grew 11% YoY • Xywav remains the #1 branded treatment for narcolepsy2, only therapy approved to treat IH, and only low-sodium oxybate Zanidatamab: • Phase 3 1L GEA top-line PFS readout expected 4Q25 • Registrational trials continue to progress with enrollment ongoing, and recruitment progressing well across active studies Updated FY25 guidance3 ranges: • Total Revenues: $4.175B – $4.275B • ANI4,5: $475M – $525M • Adjusted EPS4,5: $7.65 – $8.45 Strong balance sheet and cash flow: • Cash6 at end of 3Q25: $2B • Sept YTD operating cash flow of $993M Modeyso: • Front-line ACTION trial >50% enrolled with 95+ ex-US sites open • Estimate interim OS analysis late 2026 or early 2027 1Sleep therapeutic area consists of Xywav, Xyrem and high-sodium oxybate AG royalties; 2Based on 3Q25 Xywav net product sales; 3Guidance provided by Jazz Pharmaceuticals as of November 5,2025; 4Non-GAAP ANI (and the related per share measure) are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures” and reconciliation tables in the Appendix; 5The projected GAAP net loss and non-GAAP ANI (and the related per share measures) are impacted by a number of items, see Appendix for more information; 6Cash, cash equivalents and investments. Oncology: • Zepzelca®: FDA-approved combination with Tecentriq® for 1L maintenance in ES-SCLC and included in NCCN Guidelines as a preferred regimen • ModeysoTM: First and only FDA-approved treatment for recurrent H3 K27M-mutant diffuse midline glioma Epidiolex®: • Epidiolex revenues grew 20% YoY Early Pipeline Development: • SAN2355 early pipeline deal expands preclinical epilepsy pipeline Focus on corporate development: • Executed Chimerix acquisition and SAN2355 license agreement expanding pipeline in rare disease
Page 6
6 Commercial Performance Sam Pearce Executive Vice President and Chief Commercial Officer November 5, 2025
Page 7
November 5, 2025 Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity 1Approximate active Xywav patients exiting quarter; 2Sleep therapeutic area consists of Xywav, Xyrem and high-sodium oxybate AG royalties; 32025 AHA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, https://doi.org/10.1161/HYP.0000000000000249; 4Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy, White et. al., https://doi.org/10.1161/HYPERTENSIONAHA.125.25730; 5Based on 3Q25 Xywav net product sales. 10,075 10,250 10,375 10,600 10,725 3,550 3,900 4,225 4,625 4,950 3Q24 4Q24 1Q25 2Q25 3Q25 ACTIVE XYWAV PATIENTS1 Narcolepsy IH Sleep2 therapeutic area: • Total sleep2 revenue of $520 million in 3Q25 • Increase of ~450 net patients QoQ; Xywav revenue grew 11% YoY • JazzCares services and field nurse educator program helping patients navigate initiation of Xywav treatment • AHA guidelines3 supported by the XYLO data4 reinforce our belief that every oxybate patient could benefit from Xywav Narcolepsy • Xywav remains the #1 branded treatment for narcolepsy5 • Benefits of reducing sodium intake and an individualized dosing regimen continue to resonate with patients and HCPs Idiopathic Hypersomnia • Continued positive momentum from investments to further build the IH market driving 1,050 IH net patient adds YTD 7 13,625 14,150 14,600 15,225 15,675
Page 8
November 5, 2025 $252 $303 3Q24 3Q25 Epidiolex: Durable Growth with High Unmet Need 8 Epidiolex is the #1 branded epilepsy treatment1 • Poised to reach blockbuster status in 2025 Growth opportunities: • Further data generation, including beyond-seizure benefits from the EpiCom2 study in TSC and nurse-reported responses to the BECOME3 survey in long-term care facilities • JazzCares suite of services along with the Nurse Navigator program helps patients, families, and HCPs navigate treatment-related topics • REST-LGS tool helping to identify adult patients with LGS • Continued opportunity to drive growth in adult patient setting 1Based on 3Q25 Epidiolex net product sales; 2Eeghen, AM, Thiele, EA, et al. Poster presented at: American Epilepsy Society 2024 Annual Meeting, December 6-10, 2024. Los Angeles, CA; 3Wrobel, N. Poster presented at: American Academy of Neurology 2025 Annual Meeting, April 5-9. San Diego, CA; 43Q25 net product sales were favorably impacted by lower gross to net deductions, driven by a release of reserves following refinement of certain accrual rates in the U.S. Net product sales ($ in millions) Revenue: +20% YoY 4
Page 9
November 5, 2025 Rely on Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols Only therapy available to patients in the U.S. who have a hypersensitivity reaction to E. coli-derived asparaginase Continued focus on: • Increased use in adolescent/young adult setting • Efforts to ensure patients switch to Rylaze at first sign of HSR or due to treatment-related issues 9 Net product sales ($ in millions) $99 $100 3Q24 3Q25 Revenue: +1% YoY
Page 10
November 5, 2025 $86 $79 3Q24 3Q25 Zepzelca: Opportunity to Redefine 1L SCLC Treatment Paradigm PIPELINE 10 FDA approved Zepzelca in combination with Tecentriq combination as first-line maintenance therapy for ES-SCLC • Opportunity to redefine the treatment paradigm in 1L maintenance • Included in NCCN Guidelines as a preferred regimen • Potential to meet significant unmet need: IMforte trial results1 showed mOS of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization • Potential to increase duration of therapy with earlier line patients • In the U.S., there are ~30,000 1L SCLC patients, with ~27,000 currently treated in the front-line2 Net product sales ($ in millions) Revenue: -8% YoY 1IMforte data presented at ASCO 2025; 2Approximate U.S. SCLC patient numbers, sources: SEER Cancer Stat Facts https://seer.cancer.gov/statfacts/html/lungb.html, accessed April 19, 2019, American Cancer Society, https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html, accessed April 12, 2019, Kantar Health Treatment Architecture SCLC July 2018, Jazz primary market research May 2019.
Page 11
November 5, 2025 Disease State Awareness & Education Branded Campaign Launch Launch Exceeding Expectations 1 2 3 First and only FDA-approved treatment for recurrent H3 K27M- mutant diffused midline glioma 11 CNS WHO Grade 4 glioma1 The most aggressive form of glioma Invariably lethal with rapid mortality Median OS: ~1 yr from diagnosis2-5 and <6 months after recurrence6 Limited surgical options and no approved therapies for H3 K27M-mutant diffuse midline glioma7,8 Strong HCP engagement Driving comprehensive launch plan Digital and NPP tactics amplified; >200 patients have received Modeyso9 Strong initial launch with $11M in 3Q25 net product sales 1Louis DN et al. Neuro Oncol. 2021;23(8):1231–1251; 2Zheng L et al. Am J Surg Pathol. 2022;26:863-871; 3Vuong et al, Frontiers in Oncology March 2022; 4Mackay A et al. Cancer Cell. 2017;32(4):520-537; 5Ostrom QT et al. Neuro Oncol. 2023;25:799-807; 6Bagley et al Cancers 2025, 17(13), 2107; 7Nabors B et al. Neuro Oncol 25(12), 2114–2116, 2023; 8Gajjar A et al. J Natl Compr Canc Netw 2025;23(3):113–130; 9At the end of 3Q25. Modeyso: Strong Initial Uptake and Early Launch Success
Page 12
12 Research & Development Robert Iannone, M.D., M.S.C.E. Executive Vice President, Global Head of Research & Development, Chief Medical Officer November 5, 2025
Page 13
November 5, 2025 Key Clinical Programs PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY Recent / Upcoming Milestones Zanidatamab Phase 3 top-line PFS readout expected 4Q25 Phase 3 confirmatory trial in 1L BTC ongoing Phase 3 EmpowHER-BC-303 trial now enrolling Phase 2 EmpowHER-BC-208 trial now enrolling Phase 2 DiscovHER-Pan-206 trial now enrolling Dordaviprone Approved by FDA on August 6, 2025 Anticipate interim OS analysis late 2026 / early 2027 JZP3507 (ONC206) Zepzelca Approved by FDA on October 2, 2025 JZP815 JZP898 Epidyolex Key Pipeline Programs 1L ES-SCLC combo with Tecentriq1 Phase 3 1L BTC Phase 3 2L SCLC confirmatory trial2 Phase 4 2L SCLC observational trial I-SPY2 Trial: neoadjuvant treatment of locally advanced BC RAF & RAS mutant tumors Solid tumors Phase 3 1L GEA (pivotal) Phase 3 BC in patients who have progressed on previous T-DXd treatment Phase 2 pan-tumor trial in HER2+ solid tumors Japan (LGS/TSC/DS) Phase 2 Recurrent H3 K27M-mutant diffuse midline glioma Phase 3 1L H3 K27M-mutant diffuse glioma (ACTION) 1IMforte study done in collaboration with F. Hoffmann-La Roche Ltd; 2Lagoon study operated by partner PharmaMar. Primary CNS Tumors Phase 2 trial in neoadjuvant and adjuvant breast cancer 13
Page 14
November 5, 2025 HERIZON-GEA-01 Trial Top-Line Readout Expected 4Q25 Trastuzumab plus physician’s choice of CAPOX or FP Zanidatamab plus tislelizumab plus physician’s choice of CAPOX or FP Patients with HER2+ GEA n = 920 (actual) Zanidatamab plus physician’s choice of CAPOX or FP Randomization (1:1:1) Active comparator Arm A Experimental Arm B Experimental Arm C 14 Study Overview: • Primary Endpoints: Progression-free survival (PFS) and overall survival (OS) • Both primary endpoints will now include full 920 intent-to-treat patient population • Patients with locally advanced, recurrent or metastatic HER2-positive stomach and esophageal cancers, including GEJ
Page 15
15 Financial Performance Phil Johnson Executive Vice President, Chief Financial Officer November 5, 2025
Page 16
November 5, 2025 Focus on 2025 Commercial Execution and Disciplined Investment Neuroscience1 Oncology Other 43% 48%$993M $941M Continue to grow and diversify commercial portfolio: • Xywav revenues of $431M in 3Q25, 11% growth YoY • Epidiolex revenues of $303M in 3Q25, 20% growth YoY • Oncology revenues of $288M in 3Q25, 1% growth YoY 3Q25 Non-GAAP ANI and EPS • Includes recognition of deferred tax asset related to Chimerix, offset by litigation settlements and acquired IPR&D expense associated with SAN2355 licensing agreement 16 $2,335M 3Q25 Non-GAAP ANI2,3 and EPS2,3 3Q24 3Q25 EPS2,4 $6.54 $8.13 3Q24 3Q25 $412M $501M ANI2,4 3Q25 Total Revenues $761M $827M $285M $288M 3Q24 3Q25 $1,055M $1,126M +7% YoY 3 3 1Neuroscience revenues include high-sodium oxybate AG royalties; 2Non-GAAP ANI (and the related per share measure) are non-GAAP financial measures; for further information see “Non-GAAP Financial Measures” and reconciliation table in the Appendix; 3GAAP net income and non-GAAP ANI (and the related per share measure) were impacted by a number of items, see Appendix for more information; 4Commencing with the first quarter of 2025, we are no longer including an adjustment for non-cash interest expense in the Company's non-GAAP adjusted financial measures and for the purposes of comparability, non-GAAP adjusted financial measures for 3Q24 have been updated to reflect this change.
Page 17
November 5, 2025 As of 8/5/2025 As of 11/5/2025 As of 8/5/2025 As of 11/5/2025 $475M - $525M As of 8/5/2025 As of 11/5/2025 $680M- $710M 2025 Non-GAAP Adjusted Guidance1; Investing to Drive Growth SG&A2 R&D2 ANI2,3 Guidance range • Includes: $324M related to litigation settlement expenses and incorporation of Chimerix SG&A • Includes: R&D costs associated with dordaviprone as well as our focus on continued portfolio optimization and prioritization $941M As of 8/5/2025 As of 11/5/2025 $1,450M- $1,500M $1,590M- $1,630M $4,150M- $4,300M $4,175M- $4,275M $730M- $780M $300M- $350M Total Revenues 17 • Narrowed 2025 total revenue guidance range • Includes: $948M in acquired IPR&D from the Chimerix acquisition and SAN2355 licensing agreement, offset by recognition of $206M deferred tax asset related to Chimerix 1Guidance provided by Jazz Pharmaceuticals as of November 5 and August 5, 2025; 2ANI, SG&A and R&D expenses are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures“ and reconciliation tables in the Appendix; 3The projected GAAP net loss and non-GAAP ANI (and the related per share measures) are impacted by a number of items, see Appendix for more information.
Page 18
18 Closing Renee Gala President and Chief Executive Officer November 5, 2025
Page 19
November 5, 2025 Well-Positioned to Deliver Meaningful Shareholder Value 19 COMMERCIAL EXECUTION Poised to reach blockbuster status Meaningful growth opportunity in IH Executing launch in 2L BTC PIPELINE CATALYSTS Phase 3 1L GEA top-line PFS data expected 4Q25 Multiple registrational trials active and enrolling patients FDA-approved combination for 1LM in ES-SCLC Phase 3 ACTION trial: Anticipate interim OS analysis late 2026 / early 2027 Zanidatamab CORPORATE DEVELOPMENT Continued focus on diversifying transactions to drive long-term growth and value Near universal adoption in U.S. pediatric protocols Operational excellence and a disciplined, strategic approach to capital allocation Dordaviprone Establishing new treatment paradigm in H3 K27M mutant DMG Zepzelca Opportunity to redefine the treatment paradigm in 1L maintenance
Page 20
20 Appendix November 5, 2025
Page 21
November 5, 2025 Glossary Acronym Definition 1L First-line 1LM First-line maintenance 2L Second-line AG Authorized generic ALL / LBL Acute lymphoblastic leukaemia / lymphoblastic lymphoma ANI Adjusted net income ASCO American Society of Clinical Oncology B Billion BC Breast cancer BTC Biliary tract cancer Chimerix Chimerix, Inc. Chimerix Acquisition Our acquisition of Chimerix on April 21, 2025 CNS Central nervous system DS Dravet syndrome DMG Diffuse midline glioma EPS Earnings per share ES Extensive-stage FDA U.S. Food and Drug Administration GAAP Generally accepted accounting principles GEA Gastroesophageal adenocarcinoma GEJ Gastroesophageal junction Acronym Definition HCP Healthcare provider HER2 Human epidermal growth factor receptor 2 HSR Hypersensitivity reaction IH Idiopathic hypersomnia IPR&D In-process research and development. LGS Lennox-Gastaut Syndrome LPS Loss per share M Millions mOS Median overall survival NCCN National Comprehensive Cancer Network NPP Non-personal promotion OS Overall survival PFS Progression-free survival QoQ Quarter-over-quarter, 3Q25 vs. 2Q25 R&D Research and development SCLC Small-cell lung cancer SG&A Selling, general and administrative T-DXd Trastuzumab deruxtecan TSC Tuberous sclerosis complex WHO World Health Organization YoY Year-over-year, 3Q25 vs. 3Q24 YTD Year to date 21
Page 22
November 5, 2025 Note: Table may not foot due to rounding. 1Non-GAAP ANI (and the related per share measure) are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”; 2GAAP net income and non-GAAP ANI for 3Q25 included an income tax benefit of $205.9 million related to the recognition of certain U.S. federal and state deferred tax assets acquired through the Chimerix Acquisition, driven by the reversal of a valuation allowance, which impacted our results by $3.34 per share on a GAAP and non-GAAP adjusted basis, litigation settlements of $151.5 million which impacted our results by $128.8 million (net of tax of $22.7 million), or $2.09 per share, on a GAAP and non-GAAP adjusted basis, and acquired IPR&D expense of $42.5 million related to our global license agreement with Saniona, which impacted our results by $36.1 million (net of tax of $6.4 million), or $0.59 per share, on a GAAP and non- GAAP adjusted basis. Cumulatively these items increased EPS by $0.66 per share on a GAAP and non-GAAP adjusted basis. 3Integration related expenses with respect to the Chimerix Acquisition; 4Commencing with the first quarter of 2025, we are no longer including an adjustment for non-cash interest expense in the Company's non-GAAP adjusted financial measures and for the purposes of comparability, non-GAAP adjusted financial measures for 3Q24 have been updated to reflect this change. In thousands, except per share amounts (unaudited) Three Months Ended September 30, 2025 2024 Net Income Diluted EPS Net Income Diluted EPS GAAP reported2 $251,412 $4.08 $215,055 $3.42 Intangible asset amortization 168,368 2.73 157,457 2.49 Share-based compensation expense 88,125 1.43 59,760 0.95 Acquisition accounting inventory fair value step-up 40,355 0.66 35,034 0.55 Integration related expenses3 16,036 0.26 — — Income tax effect of above adjustments (63,643) (1.03) (54,947) (0.87) Non-GAAP adjusted1,2,4 $500,653 $8.13 $412,359 $6.54 Weighted-average ordinary shares used in diluted per share calculations – GAAP and non-GAAP1 61,606 63,174 Reconciliation of GAAP Reported to Non-GAAP Adjusted Information1 22
Page 23
November 5, 2025 In millions, except per share amounts (unaudited) 2025 Guidance Net Income / (Loss) Diluted EPS / (LPS) GAAP2 $(435) - $(315) $(7.10) - $(5.20) Intangible asset amortization 610 - 660 9.85 - 10.65 Share-based compensation expense 280 - 300 4.50 - 4.85 Acquisition accounting inventory fair value step-up 135 - 155 2.15 - 2.50 Integration related expenses3 25 - 35 0.40 - 0.55 Income tax effect of above adjustments (210) - (240) (3.40) - (3.85) Effect of potentially dilutive ordinary shares on non-GAAP adjusted EPS - 0.10 - 0.15 Non-GAAP adjusted1,2 $475 - $525 $7.65 - $8.45 Weighted-average ordinary shares used in per share calculations - GAAP 61 Weighted-average ordinary shares used in per share calculations - non-GAAP 62 In millions (unaudited) 2025 Guidance SG&A R&D GAAP expenses $1,786 - $1,846 $771 - $810 Share-based compensation expense (179) - (192) (83) - (89) Integration related expense (17) - (24) (8) - (11) Non-GAAP adjusted expenses1 $1,590 - $1,630 $680 - $710 Reconciliation of GAAP to Non-GAAP Adjusted1 2025 Guidance as of November 5, 2025 Note: Table may not foot due to rounding. 1Non-GAAP ANI (and the related per share measure), SG&A and R&D expenses are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”; 2The projected GAAP net loss and non-GAAP ANI (and the related per share measure ) include acquired IPR&D expenses related to the Chimerix Acquisition of $905.4 million and Saniona licensing agreement of $42.5 million, litigation settlements of $323.5 million; offset by an income tax benefit of $205.9 million related to the recognition of certain U.S. federal and state deferred tax assets acquired through the Chimerix Acquisition, driven by the reversal of a valuation allowance, which impact the Company's projected results by $1.0 billion (net of tax of $54.8 million), or $16.40 per share and $16.30 per share, on a GAAP and non-GAAP adjusted basis, respectively; 3Integration related expenses with respect to the Chimerix Acquisition. 23
Page 24
November 5, 2025 In millions, except per share amounts (unaudited) 2025 Guidance Net Income / (Loss) Diluted EPS / (LPS) GAAP $(565) - $(450) $(9.25) - $(7.50) Intangible asset amortization 610 - 660 9.70 - 10.60 Share-based compensation expense 240 - 270 3.80 - 4.35 Acquisition accounting inventory fair value step-up 135 - 155 2.15 - 2.50 Integration related expenses2 20 - 25 0.30 - 0.40 Income tax effect of above adjustments (215) - (235) (3.40) - (3.85) Effect of potentially dilutive ordinary shares on non-GAAP adjusted EPS - 0.05 - 0.20 Non-GAAP adjusted1 $300 - $350 $4.80 - $5.60 Weighted-average ordinary shares used in per share calculations - GAAP 61 - 62 Weighted-average ordinary shares used in per share calculations - non-GAAP 62 - 63 In millions (unaudited) 2025 Guidance SG&A R&D GAAP expenses $1,620 - $1,693 $805 - $865 Share-based compensation expense (154) - (173) (72) - (81) Integration related expense (16) - (20) (3) - (4) Non-GAAP adjusted expenses1 $1,450 - $1,500 $730 - $780 Reconciliation of GAAP to Non-GAAP Adjusted1 2025 Guidance as of August 5, 2025 Note: Table may not foot due to rounding. 1Non-GAAP ANI (and the related per share measure), SG&A and R&D expenses are non-GAAP financial measures; for further information, see “Non-GAAP Financial Measures”; 2Integration related expenses with respect to the Chimerix Acquisition. 24